Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: An analysis of a randomized controlled trial

Adam Bress, Rick A Kittles, Coady Wing, Stanley E. Hooker, Andrea King

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives To determine whether there were differential quit rates between African Americans (AA) and European Americans with the experimental treatment naltrexone, and examine the role of genetic ancestry on these outcomes among AAs. Methods: Data from a previous randomized trial of 315 smokers to naltrexone versus placebo were reanalyzed using West African (WA) genetic ancestry to define subpopulations. Logistic regression models were used to estimate treatment effects on early and end of treatment quit rates, by race and WA ancestry. Results: Among European Americans (n= 136), naltrexone significantly increased quit rates at 4 weeks (62 vs. 43%, P = 0.03) with directional, but not statistically significant effects at 12 weeks (30 vs. 18%, P=0.12). In contrast, among the AAs (n =95), quit rates did not differ between naltrexone and placebo groups at either interval (4 weeks: 43 vs. 32%, P =0.27; 12 weeks: 22 vs. 18%, P= 0.60). A median split was conducted in AAs for WA ancestry. Among AAs with low WA ancestry, quit rates were significantly higher with naltrexone compared with placebo (60 vs. 27%, P =0.03). There was no advantage in quit rates with naltrexone for the high WA ancestry group. Conclusion: Naltrexone efficacy for smoking cessation varies across AA individuals with different levels of WA ancestry. These results suggest that genetic background may partially explain racial differences in drug response.

Original languageEnglish (US)
Pages (from-to)305-312
Number of pages8
JournalPharmacogenetics and Genomics
Volume25
Issue number6
DOIs
StatePublished - May 15 2015

Fingerprint

Naltrexone
Smoking Cessation
African Americans
Randomized Controlled Trials
Placebos
Logistic Models
Therapeutics
Pharmaceutical Preparations

Keywords

  • African Americans
  • Ancestry
  • Naltrexone
  • Pharmacogenomics
  • Smoking cessation

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans : An analysis of a randomized controlled trial. / Bress, Adam; Kittles, Rick A; Wing, Coady; Hooker, Stanley E.; King, Andrea.

In: Pharmacogenetics and Genomics, Vol. 25, No. 6, 15.05.2015, p. 305-312.

Research output: Contribution to journalArticle

@article{3d1453883fc64bba8a86d5d9fb037fc8,
title = "Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: An analysis of a randomized controlled trial",
abstract = "Objectives To determine whether there were differential quit rates between African Americans (AA) and European Americans with the experimental treatment naltrexone, and examine the role of genetic ancestry on these outcomes among AAs. Methods: Data from a previous randomized trial of 315 smokers to naltrexone versus placebo were reanalyzed using West African (WA) genetic ancestry to define subpopulations. Logistic regression models were used to estimate treatment effects on early and end of treatment quit rates, by race and WA ancestry. Results: Among European Americans (n= 136), naltrexone significantly increased quit rates at 4 weeks (62 vs. 43{\%}, P = 0.03) with directional, but not statistically significant effects at 12 weeks (30 vs. 18{\%}, P=0.12). In contrast, among the AAs (n =95), quit rates did not differ between naltrexone and placebo groups at either interval (4 weeks: 43 vs. 32{\%}, P =0.27; 12 weeks: 22 vs. 18{\%}, P= 0.60). A median split was conducted in AAs for WA ancestry. Among AAs with low WA ancestry, quit rates were significantly higher with naltrexone compared with placebo (60 vs. 27{\%}, P =0.03). There was no advantage in quit rates with naltrexone for the high WA ancestry group. Conclusion: Naltrexone efficacy for smoking cessation varies across AA individuals with different levels of WA ancestry. These results suggest that genetic background may partially explain racial differences in drug response.",
keywords = "African Americans, Ancestry, Naltrexone, Pharmacogenomics, Smoking cessation",
author = "Adam Bress and Kittles, {Rick A} and Coady Wing and Hooker, {Stanley E.} and Andrea King",
year = "2015",
month = "5",
day = "15",
doi = "10.1097/FPC.0000000000000138",
language = "English (US)",
volume = "25",
pages = "305--312",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans

T2 - An analysis of a randomized controlled trial

AU - Bress, Adam

AU - Kittles, Rick A

AU - Wing, Coady

AU - Hooker, Stanley E.

AU - King, Andrea

PY - 2015/5/15

Y1 - 2015/5/15

N2 - Objectives To determine whether there were differential quit rates between African Americans (AA) and European Americans with the experimental treatment naltrexone, and examine the role of genetic ancestry on these outcomes among AAs. Methods: Data from a previous randomized trial of 315 smokers to naltrexone versus placebo were reanalyzed using West African (WA) genetic ancestry to define subpopulations. Logistic regression models were used to estimate treatment effects on early and end of treatment quit rates, by race and WA ancestry. Results: Among European Americans (n= 136), naltrexone significantly increased quit rates at 4 weeks (62 vs. 43%, P = 0.03) with directional, but not statistically significant effects at 12 weeks (30 vs. 18%, P=0.12). In contrast, among the AAs (n =95), quit rates did not differ between naltrexone and placebo groups at either interval (4 weeks: 43 vs. 32%, P =0.27; 12 weeks: 22 vs. 18%, P= 0.60). A median split was conducted in AAs for WA ancestry. Among AAs with low WA ancestry, quit rates were significantly higher with naltrexone compared with placebo (60 vs. 27%, P =0.03). There was no advantage in quit rates with naltrexone for the high WA ancestry group. Conclusion: Naltrexone efficacy for smoking cessation varies across AA individuals with different levels of WA ancestry. These results suggest that genetic background may partially explain racial differences in drug response.

AB - Objectives To determine whether there were differential quit rates between African Americans (AA) and European Americans with the experimental treatment naltrexone, and examine the role of genetic ancestry on these outcomes among AAs. Methods: Data from a previous randomized trial of 315 smokers to naltrexone versus placebo were reanalyzed using West African (WA) genetic ancestry to define subpopulations. Logistic regression models were used to estimate treatment effects on early and end of treatment quit rates, by race and WA ancestry. Results: Among European Americans (n= 136), naltrexone significantly increased quit rates at 4 weeks (62 vs. 43%, P = 0.03) with directional, but not statistically significant effects at 12 weeks (30 vs. 18%, P=0.12). In contrast, among the AAs (n =95), quit rates did not differ between naltrexone and placebo groups at either interval (4 weeks: 43 vs. 32%, P =0.27; 12 weeks: 22 vs. 18%, P= 0.60). A median split was conducted in AAs for WA ancestry. Among AAs with low WA ancestry, quit rates were significantly higher with naltrexone compared with placebo (60 vs. 27%, P =0.03). There was no advantage in quit rates with naltrexone for the high WA ancestry group. Conclusion: Naltrexone efficacy for smoking cessation varies across AA individuals with different levels of WA ancestry. These results suggest that genetic background may partially explain racial differences in drug response.

KW - African Americans

KW - Ancestry

KW - Naltrexone

KW - Pharmacogenomics

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=84929237797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929237797&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000138

DO - 10.1097/FPC.0000000000000138

M3 - Article

C2 - 25918964

AN - SCOPUS:84929237797

VL - 25

SP - 305

EP - 312

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 6

ER -